@article{ref1,
title="Updated ME/CFS prevalence estimates reflecting post-COVID increases and associated economic costs and funding implications",
journal="Fatigue: biomedicine, health and behavior",
year="2022",
author="Mirin, A.A. and Dimmock, M.E. and Jason, L.A.",
volume="10",
number="2",
pages="83-93",
abstract="In this article, we update our earlier analyses of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) economic impact and its National Institutes of Health (NIH) funding versus disease burden, taking into account the anticipated new cases of ME/CFS resulting from COVID-19. Prior to the COVID pandemic, we estimated a United States ME/CFS prevalence of 1.5 million and an annual economic impact of $36-51 billion. Now, due to COVID and its resulting post-acute sequalae, we estimate total ME/CFS prevalence could rise to between five and nine million. This would incur an annual U.S. economic impact of $149 to $362 billion in medical expenses and lost income, exclusive of other costs, such as disability benefits, social services, and lost wages of caretakers. NIH funding for ME/CFS research would need to expand from the current amount of $15 million per year to approximately $472-$600 million annually, up to a 40-fold increase, to be commensurate with that of similarly burdensome diseases. © 2022 IACFS/ME.<p /><p>Language: en</p>",
language="en",
issn="2164-1846",
doi="10.1080/21641846.2022.2062169",
url="http://dx.doi.org/10.1080/21641846.2022.2062169"
}